Zonglin Deng, Zhihong Gong,
Roberd M. Bostick, Franklin G.
Berger, James R. Hebert,
and Dawen Xie
 Interleukin-6 (IL-6) is an important pro-inflammatory cytokine that has
multiple effects on inflammation and cell growth. A genetic polymorphism
within the IL-6 promoter region (-174G/C) modulates IL-6 expression in
vitro and in vivo. Researching the association between IL-6 -174G/C
polymorphism and risk of colorectal neoplasia, whether the association
differs according to adenoma characteristics, and whether IL-6 genotype
interacts with environmental factors to modify risk for incident, sporadic
colorectal adenomas, findings suggests that the IL-6 -174G/C polymorphism,
in conjunction with other risk factors, may reduce risk for colorectal
adenomas.
Read full article
Joseph H. Coggin, Jr. Ph.D., Emeritus Professor, University of South Alabama College of Medicine
 Oncologists and medical scientists have longed to discover a universal “vaccination” procedure and a method for monitoring and predicting therapy outcomes in patients with all types of human cancer. Once these objectives are achieved, it is generally accepted that the critical mechanisms by which cancers develop and spread will be revealed. The emerging technology licensed recently to Investors Medical Fund, LLC [IMF] of Tampa, FL by South Alabama Medical Sciences Foundation (SAMSF) contains theoretical and immunological scientific content, which opens a potential avenue to achieve these long-sought anti-cancer objectives.
Read full article
|
